Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 761 entries
Sorted by: Best Match Show Resources per page
Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus.

JAAD case reports

Ansari U, Henderson LI, Stott G, Parr K.
PMID: 28229123
JAAD Case Rep. 2017 Feb 03;3(1):67-69. doi: 10.1016/j.jdcr.2016.12.005. eCollection 2017 Jan.

No abstract available.

Cite
Ansari U, Henderson LI, Stott G, et al. Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus. JAAD Case Rep. 2017;3(1):67-69doi: 10.1016/j.jdcr.2016.12.005.
Ansari, U., Henderson, L. I., Stott, G., & Parr, K. (2017). Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus. JAAD case reports, 3(1), 67-69. https://doi.org/10.1016/j.jdcr.2016.12.005
Ansari, Umer, et al. "Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus." JAAD case reports vol. 3,1 (2017): 67-69. doi: https://doi.org/10.1016/j.jdcr.2016.12.005
Ansari U, Henderson LI, Stott G, Parr K. Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus. JAAD Case Rep. 2017 Feb 03;3(1):67-69. doi: 10.1016/j.jdcr.2016.12.005. eCollection 2017 Jan. PMID: 28229123; PMCID: PMC5311428.
Copy Download .nbib Format: NLM
New treatment strategies for hepatitis C infection.

World journal of hepatology

Ermis F, Senocak Tasci E.
PMID: 26301052
World J Hepatol. 2015 Aug 18;7(17):2100-9. doi: 10.4254/wjh.v7.i17.2100.

Hepatitis C infection can lead to cirrhosis and hepatocellular carcinoma and it is an important cause of mortality and morbidity. Achieving a sustained virological response has been the major aim for decades. Interferon treatment was the primarily developed therapy...

Cite
Ermis F, Senocak Tasci E. New treatment strategies for hepatitis C infection. World J Hepatol. 2015;7(17):2100-9doi: 10.4254/wjh.v7.i17.2100.
Ermis, F., & Senocak Tasci, E. (2015). New treatment strategies for hepatitis C infection. World journal of hepatology, 7(17), 2100-9. https://doi.org/10.4254/wjh.v7.i17.2100
Ermis, Fatih, and Senocak Tasci, Elif. "New treatment strategies for hepatitis C infection." World journal of hepatology vol. 7,17 (2015): 2100-9. doi: https://doi.org/10.4254/wjh.v7.i17.2100
Ermis F, Senocak Tasci E. New treatment strategies for hepatitis C infection. World J Hepatol. 2015 Aug 18;7(17):2100-9. doi: 10.4254/wjh.v7.i17.2100. PMID: 26301052; PMCID: PMC4539403.
Copy Download .nbib Format: NLM
Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals.

GMS ophthalmology cases

Prud'homme S, Nevens F, Casteels I.
PMID: 27625964
GMS Ophthalmol Cases. 2016 Apr 04;6:Doc05. doi: 10.3205/oc000042. eCollection 2016.

We report a patient with a bilateral optic anterior ischemic neuropathy as an extrahepatic complication of a chronic hepatitis C (HCV) infection. The patient presented with a bilateral visual acuity loss and bilateral optic disc oedema. The optic neuropathy...

Cite
Prud'homme S, Nevens F, Casteels I. Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals. GMS Ophthalmol Cases. 2016;6:Doc05doi: 10.3205/oc000042.
Prud'homme, S., Nevens, F., & Casteels, I. (2016). Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals. GMS ophthalmology cases, 6Doc05. https://doi.org/10.3205/oc000042
Prud'homme, Sylvie, et al. "Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals." GMS ophthalmology cases vol. 6 (2016): Doc05. doi: https://doi.org/10.3205/oc000042
Prud'homme S, Nevens F, Casteels I. Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals. GMS Ophthalmol Cases. 2016 Apr 04;6:Doc05. doi: 10.3205/oc000042. eCollection 2016. PMID: 27625964; PMCID: PMC5015795.
Copy Download .nbib Format: NLM
Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients.

Hospital pharmacy

Ahmad YK, Tawfeek S, Sharaf-Eldin M, Elbatea HE, Kobtan A, El-Kalla F, Badawi R, Abd-Elsalam S.
PMID: 28515509
Hosp Pharm. 2017 Apr;52(4):294-301. doi: 10.1310/hpj5204-294.

No abstract available.

Cite
Ahmad YK, Tawfeek S, Sharaf-Eldin M, et al. Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients. Hosp Pharm. 2017;52(4):294-301doi: 10.1310/hpj5204-294.
Ahmad, Y. K., Tawfeek, S., Sharaf-Eldin, M., Elbatea, H. E., Kobtan, A., El-Kalla, F., Badawi, R., & Abd-Elsalam, S. (2017). Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients. Hospital pharmacy, 52(4), 294-301. https://doi.org/10.1310/hpj5204-294
Ahmad, Youssef K, et al. "Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients." Hospital pharmacy vol. 52,4 (2017): 294-301. doi: https://doi.org/10.1310/hpj5204-294
Ahmad YK, Tawfeek S, Sharaf-Eldin M, Elbatea HE, Kobtan A, El-Kalla F, Badawi R, Abd-Elsalam S. Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients. Hosp Pharm. 2017 Apr;52(4):294-301. doi: 10.1310/hpj5204-294. PMID: 28515509; PMCID: PMC5424834.
Copy Download .nbib Format: NLM
An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin.

Clinical case reports

Poordad F, Lawitz E, Gutierrez JA, Guerrero J, Speeg K, Swenson ES.
PMID: 28396749
Clin Case Rep. 2017 Feb 03;5(4):371-375. doi: 10.1002/ccr3.841. eCollection 2017 Apr.

This case suggests that initiation of HCV therapy immediately after liver transplantation with well-tolerated, all-oral regimens may achieve a virologic cure in HCV-positive recipients, thus preventing post-transplant HCV recurrence and associated disease progression. This strategy may broaden utilization of...

Cite
Poordad F, Lawitz E, Gutierrez JA, et al. An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clin Case Rep. 2017;5(4):371-375doi: 10.1002/ccr3.841.
Poordad, F., Lawitz, E., Gutierrez, J. A., Guerrero, J., Speeg, K., & Swenson, E. S. (2017). An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clinical case reports, 5(4), 371-375. https://doi.org/10.1002/ccr3.841
Poordad, Fred, et al. "An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin." Clinical case reports vol. 5,4 (2017): 371-375. doi: https://doi.org/10.1002/ccr3.841
Poordad F, Lawitz E, Gutierrez JA, Guerrero J, Speeg K, Swenson ES. An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clin Case Rep. 2017 Feb 03;5(4):371-375. doi: 10.1002/ccr3.841. eCollection 2017 Apr. PMID: 28396749; PMCID: PMC5378822.
Copy Download .nbib Format: NLM
Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions.

Current infectious disease reports

Johnson SW, Thompson DK, Raccor B.
PMID: 28421422
Curr Infect Dis Rep. 2017 Jun;19(6):22. doi: 10.1007/s11908-017-0578-5.

PURPOSE OF REVIEW: Direct-acting antiviral agents (DAAs) have markedly improved the prognosis of hepatitis C virus (HCV)-genotype 3 (GT3), a highly prevalent infection worldwide. However, in patients with hepatic fibrosis, cirrhosis, or hepatocellular carcinoma (HCC), GT3 infection presents a...

Cite
Johnson SW, Thompson DK, Raccor B. Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions. Curr Infect Dis Rep. 2017;19(6):22doi: 10.1007/s11908-017-0578-5.
Johnson, S. W., Thompson, D. K., & Raccor, B. (2017). Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions. Current infectious disease reports, 19(6), 22. https://doi.org/10.1007/s11908-017-0578-5
Johnson, Steven W, et al. "Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions." Current infectious disease reports vol. 19,6 (2017): 22. doi: https://doi.org/10.1007/s11908-017-0578-5
Johnson SW, Thompson DK, Raccor B. Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions. Curr Infect Dis Rep. 2017 Jun;19(6):22. doi: 10.1007/s11908-017-0578-5. PMID: 28421422.
Copy Download .nbib Format: NLM
Spontaneous remission of hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic hepatitis C.

Hepatology research : the official journal of the Japan Society of Hepatology

Sato K, Kobayashi T, Yamazaki Y, Takakusagi S, Horiguchi N, Kakizaki S, Kusano M, Yamada M.
PMID: 28422376
Hepatol Res. 2017 Nov;47(12):1346-1353. doi: 10.1111/hepr.12905. Epub 2017 May 24.

The administration of direct-acting antiviral agents (DAAs) to treat hepatitis C virus (HCV) infection has been reported to cause hepatitis B virus (HBV) reactivation. However, the actual conditions of HBV reactivation and the ideal timing of medical intervention have...

Cite
Sato K, Kobayashi T, Yamazaki Y, et al. Spontaneous remission of hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic hepatitis C. Hepatol Res. 2017;47(12):1346-1353doi: 10.1111/hepr.12905.
Sato, K., Kobayashi, T., Yamazaki, Y., Takakusagi, S., Horiguchi, N., Kakizaki, S., Kusano, M., & Yamada, M. (2017). Spontaneous remission of hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic hepatitis C. Hepatology research : the official journal of the Japan Society of Hepatology, 47(12), 1346-1353. https://doi.org/10.1111/hepr.12905
Sato, Ken, et al. "Spontaneous remission of hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic hepatitis C." Hepatology research : the official journal of the Japan Society of Hepatology vol. 47,12 (2017): 1346-1353. doi: https://doi.org/10.1111/hepr.12905
Sato K, Kobayashi T, Yamazaki Y, Takakusagi S, Horiguchi N, Kakizaki S, Kusano M, Yamada M. Spontaneous remission of hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic hepatitis C. Hepatol Res. 2017 Nov;47(12):1346-1353. doi: 10.1111/hepr.12905. Epub 2017 May 24. PMID: 28422376.
Copy Download .nbib Format: NLM
Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin.

Biology

Kanda T, Nakamura M, Yasui S, Haga Y, Tawada A, Suzuki E, Ooka Y, Takahashi K, Sasaki R, Wu S, Nakamoto S, Arai M, Imazeki F, Yokosuka O.
PMID: 28486403
Biology (Basel). 2017 May 09;6(2). doi: 10.3390/biology6020030.

The aim of this study was to characterize the treatment response and tolerability of sofosbuvir plus ribavirin therapies in Japanese patients infected with hepatitis C virus (HCV) genotype (GT)-2. This retrospective study analyzed 114 Japanese HCV GT-2 patients treated...

Cite
Kanda T, Nakamura M, Yasui S, et al. Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. Biology (Basel). 2017;6(2)doi: 10.3390/biology6020030.
Kanda, T., Nakamura, M., Yasui, S., Haga, Y., Tawada, A., Suzuki, E., Ooka, Y., Takahashi, K., Sasaki, R., Wu, S., Nakamoto, S., Arai, M., Imazeki, F., & Yokosuka, O. (2017). Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. Biology, 6(2), . https://doi.org/10.3390/biology6020030
Kanda, Tatsuo, et al. "Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin." Biology vol. 6,2 (2017). doi: https://doi.org/10.3390/biology6020030
Kanda T, Nakamura M, Yasui S, Haga Y, Tawada A, Suzuki E, Ooka Y, Takahashi K, Sasaki R, Wu S, Nakamoto S, Arai M, Imazeki F, Yokosuka O. Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. Biology (Basel). 2017 May 09;6(2). doi: 10.3390/biology6020030. PMID: 28486403; PMCID: PMC5485477.
Copy Download .nbib Format: NLM
Hepatitis C genotype 4: The past, present, and future.

World journal of hepatology

Abdel-Ghaffar TY, Sira MM, El Naghi S.
PMID: 26668691
World J Hepatol. 2015 Dec 08;7(28):2792-810. doi: 10.4254/wjh.v7.i28.2792.

Hepatitis C virus (HCV) genotype (GT) 4 represents 12%-15% (15-18 million) of total global HCV infection. It is prevalent in Northern and Equatorial Africa and the Middle East, and is also present in some countries in Europe. GT-4 (and...

Cite
Abdel-Ghaffar TY, Sira MM, El Naghi S. Hepatitis C genotype 4: The past, present, and future. World J Hepatol. 2015;7(28):2792-810doi: 10.4254/wjh.v7.i28.2792.
Abdel-Ghaffar, T. Y., Sira, M. M., & El Naghi, S. (2015). Hepatitis C genotype 4: The past, present, and future. World journal of hepatology, 7(28), 2792-810. https://doi.org/10.4254/wjh.v7.i28.2792
Abdel-Ghaffar, Tawhida Y, et al. "Hepatitis C genotype 4: The past, present, and future." World journal of hepatology vol. 7,28 (2015): 2792-810. doi: https://doi.org/10.4254/wjh.v7.i28.2792
Abdel-Ghaffar TY, Sira MM, El Naghi S. Hepatitis C genotype 4: The past, present, and future. World J Hepatol. 2015 Dec 08;7(28):2792-810. doi: 10.4254/wjh.v7.i28.2792. PMID: 26668691; PMCID: PMC4670951.
Copy Download .nbib Format: NLM
Ledipasvir with sofosbuvir.

Australian prescriber

[No authors listed]
PMID: 26843718
Aust Prescr. 2015 Dec;38(6):219-21. doi: 10.18773/austprescr.2015.078. Epub 2015 Oct 14.

No abstract available.

Cite
Ledipasvir with sofosbuvir. Aust Prescr. 2015;38(6):219-21doi: 10.18773/austprescr.2015.078.
(2015). Ledipasvir with sofosbuvir. Australian prescriber, 38(6), 219-21. https://doi.org/10.18773/austprescr.2015.078
"Ledipasvir with sofosbuvir." Australian prescriber vol. 38,6 (2015): 219-21. doi: https://doi.org/10.18773/austprescr.2015.078
Ledipasvir with sofosbuvir. Aust Prescr. 2015 Dec;38(6):219-21. doi: 10.18773/austprescr.2015.078. Epub 2015 Oct 14. PMID: 26843718; PMCID: PMC4674024.
Copy Download .nbib Format: NLM
Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C.

Journal of clinical and translational hepatology

Saab S, Rheem J, Jimenez MA, Fong TM, Mai MH, Kachadoorian CA, Esmailzadeh NL, Bau SN, Kang S, Ramirez SD, Grotts J, Choi G, Durazo FA, El-Kabany MM, Han SB, Busuttil RW.
PMID: 28660147
J Clin Transl Hepatol. 2017 Jun 28;5(2):101-108. doi: 10.14218/JCTH.2016.00070. Epub 2017 May 14.

No abstract available.

Cite
Saab S, Rheem J, Jimenez MA, et al. Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. J Clin Transl Hepatol. 2017;5(2):101-108doi: 10.14218/JCTH.2016.00070.
Saab, S., Rheem, J., Jimenez, M. A., Fong, T. M., Mai, M. H., Kachadoorian, C. A., Esmailzadeh, N. L., Bau, S. N., Kang, S., Ramirez, S. D., Grotts, J., Choi, G., Durazo, F. A., El-Kabany, M. M., Han, S. B., & Busuttil, R. W. (2017). Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. Journal of clinical and translational hepatology, 5(2), 101-108. https://doi.org/10.14218/JCTH.2016.00070
Saab, Sammy, et al. "Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C." Journal of clinical and translational hepatology vol. 5,2 (2017): 101-108. doi: https://doi.org/10.14218/JCTH.2016.00070
Saab S, Rheem J, Jimenez MA, Fong TM, Mai MH, Kachadoorian CA, Esmailzadeh NL, Bau SN, Kang S, Ramirez SD, Grotts J, Choi G, Durazo FA, El-Kabany MM, Han SB, Busuttil RW. Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. J Clin Transl Hepatol. 2017 Jun 28;5(2):101-108. doi: 10.14218/JCTH.2016.00070. Epub 2017 May 14. PMID: 28660147; PMCID: PMC5472930.
Copy Download .nbib Format: NLM
Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin.

Case reports in gastroenterology

Sasaki R, Kanda T, Ohtsuka M, Yasui S, Haga Y, Nakamura M, Yokoyama M, Wu S, Nakamoto S, Arai M, Maruyama H, Miyazaki M, Yokosuka O.
PMID: 27721720
Case Rep Gastroenterol. 2016 Jul 20;10(2):366-372. doi: 10.1159/000447423. eCollection 2016.

Direct-acting antivirals (DAAs) are relatively safe and highly effective for the eradication of hepatitis C virus (HCV) in liver transplant recipients. In this case study, we present a female with a graft reinfected with HCV genotype 2 who was...

Cite
Sasaki R, Kanda T, Ohtsuka M, et al. Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin. Case Rep Gastroenterol. 2016;10(2):366-372doi: 10.1159/000447423.
Sasaki, R., Kanda, T., Ohtsuka, M., Yasui, S., Haga, Y., Nakamura, M., Yokoyama, M., Wu, S., Nakamoto, S., Arai, M., Maruyama, H., Miyazaki, M., & Yokosuka, O. (2016). Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin. Case reports in gastroenterology, 10(2), 366-372. https://doi.org/10.1159/000447423
Sasaki, Reina, et al. "Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin." Case reports in gastroenterology vol. 10,2 (2016): 366-372. doi: https://doi.org/10.1159/000447423
Sasaki R, Kanda T, Ohtsuka M, Yasui S, Haga Y, Nakamura M, Yokoyama M, Wu S, Nakamoto S, Arai M, Maruyama H, Miyazaki M, Yokosuka O. Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin. Case Rep Gastroenterol. 2016 Jul 20;10(2):366-372. doi: 10.1159/000447423. eCollection 2016. PMID: 27721720; PMCID: PMC5043295.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 761 entries